{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001178670","name":"ALNYLAM PHARMACEUTICALS, INC.","summary":"Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company pioneering RNAi therapeutics—medicines based on RNA interference that silence disease-causing genes. The company has six approved products: AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), Leqvio (inclisiran, commercialized by Novartis), and Qfitlia (fitusiran, commercialized by Sanofi). Alnylam targets rare and prevalent diseases using GalNAc conjugate and lipid nanoparticle delivery technologies, with more than 20 active clinical programs.","people":[],"products":[{"name":"AMVUTTRA (vutrisiran)","type":"service","description":"RNAi therapeutic approved for hATTR amyloidosis with polyneuropathy and cardiomyopathy in adults across multiple markets."},{"name":"ONPATTRO (patisiran)","type":"service","description":"RNAi therapeutic approved for polyneuropathy of hATTR amyloidosis in adults; also approved for ATTR cardiomyopathy in Brazil."},{"name":"GIVLAARI (givosiran)","type":"service","description":"RNAi therapeutic approved for acute hepatic porphyria in adults and adolescents in the U.S., EU, and other countries."},{"name":"OXLUMO (lumasiran)","type":"service","description":"RNAi therapeutic approved for primary hyperoxaluria type 1 in pediatric and adult patients in the U.S., EU, and UK."},{"name":"Leqvio (inclisiran)","type":"service","description":"RNAi therapeutic developed and commercialized by Novartis for hypercholesterolemia and ASCVD; approved in multiple regions."},{"name":"Qfitlia (fitusiran)","type":"service","description":"RNAi therapeutic commercialized by Sanofi for hemophilia A or B prophylaxis; approved by FDA in March 2025."},{"name":"nucresiran","type":"platform","description":"Next-generation investigational RNAi therapeutic in Phase 3 trials for ATTR amyloidosis polyneuropathy and cardiomyopathy."},{"name":"zilebesiran","type":"platform","description":"Investigational subcutaneous RNAi therapeutic targeting angiotensinogen for hypertension; in Phase 3 ZENITH trial with Roche."},{"name":"mivelsiran (ALN-APP)","type":"platform","description":"Investigational RNAi therapeutic targeting amyloid precursor protein for cerebral amyloid angiopathy and Alzheimer's disease."},{"name":"cemdisiran","type":"platform","description":"Investigational RNAi therapeutic for complement-mediated diseases being advanced by collaborator Regeneron in Phase 3 trials."}],"partnerships":[{"partner_name":"Novartis AG","partnership_type":"licensing","description":"Novartis develops and commercializes Leqvio (inclisiran) globally under a collaboration agreement with Alnylam.","start_date":null},{"partner_name":"Genzyme Corporation (Sanofi)","partnership_type":"licensing","description":"Sanofi commercializes Qfitlia (fitusiran) under a collaboration agreement with Alnylam.","start_date":null},{"partner_name":"F. Hoffmann-La Roche Ltd. and Genentech, Inc.","partnership_type":"development","description":"Worldwide strategic collaboration for joint development and commercialization of zilebesiran for hypertension, established in 2023.","start_date":null},{"partner_name":"Regeneron Pharmaceuticals, Inc.","partnership_type":"development","description":"Regeneron advances cemdisiran in Phase 3 clinical trials for complement-mediated diseases including myasthenia gravis and geographic atrophy.","start_date":null}],"affiliations":[],"origin":{"leaf":"d43d39d5b46b29a73e97e47915c76b649937088cfd5758629df4932943a653ee","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"f39b55283c301ea0a11692f0f51b92254c7462476549ef2c02dbc6eda289c737","parent":"70e6c254dc019cb511e6bf8919a24f87e6af18f6e8b406e3f08f19d380af1d18","source":"0001628280-26-007497","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":105,"hourly_limit":500,"remaining":395,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}